Broader Indications For Tarceva As Astellas Scales Back In The U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
The Japanese pharma is consolidating its U.S. operations, including the shuttering of OSI, where Tarceva initially was developed, as the cancer drug gains another indication with a companion diagnostic.